SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03217253

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction

This phase I trial studies the best dose and side effects of tazemetostat in treating patients with solid tumors or B-cell lymphomas with liver dysfunction that have spread to other places in the body or cannot be removed by surgery. Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT03217253 Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma Liver Dysfunction Metastatic Malignant Solid Neoplasm Stage III Hepatocellular Carcinoma AJCC v7 Stage IIIA Hepatocellular Carcinoma AJCC v7 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v7 Stage IVA Hepatocellular Carcinoma AJCC v7 Stage IVB Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm
MeSH: Lymphoma Carcinoma Neoplasms Lymphoma, Non-Hodgkin Carcinoma, Hepatocellular Lymphoma, B-Cell Liver Diseases
HPO: Abnormality of the liver B-cell lymphoma Carcinoma Decreased liver function Elevated hepatic transaminase Hepatocellular carcinoma Lymphoma Neoplasm Non-Hodgkin lymphoma

3 Interventions

Name: Laboratory Biomarker Analysis

Description: Correlative studies

Type: Other

Treatment (tazemetostat)

Name: Pharmacological Study

Description: Correlative studies

Type: Other

Treatment (tazemetostat)

Name: Tazemetostat

Description: Given PO

Type: Drug

Treatment (tazemetostat)


Primary Outcomes

Description: Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a sub-analysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to study treatment.

Measure: Incidence of adverse events of tazemetostat in patients with varying degrees of hepatic dysfunction assessed using Common Terminology Criteria for Adverse Events version 5.0

Time: Up to 2 years

Description: RP2D will be determined.

Measure: Recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction

Time: Up to 2 years

Secondary Outcomes

Description: Plasma concentrations will be measured by Q2 Solutions using a validated Liquid chromatography (LC)/mass spectrometry (MS)/MS assay. Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. Given the small sample size, and exploratory nature of these endpoints, all pharmacodynamic analyses conducted will be considered exploratory. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Pharmacokinetic (PK) profiles of tazemetostat in patients with varying degrees of hepatic dysfunction

Time: Up to course 4 day 1 (day 85)

Description: Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Antitumor activity of tazemetostat

Time: Up to 2 years

Description: Molecular and clinical predictors of clinical outcomes will be investigated using logistic regression and Cox proportional hazards models. Potential predictors include clinical predictors and molecular correlates. Descriptive statistics and plotting of data will also be used to better understand potential relationships. All analyses will be considered exploratory and inference will be performed with appropriate caution.

Measure: Antitumor activity of tazemetostat in population with tumors with aberrations in EZH2 or SWI/SNF complex pathways

Time: Up to 2 years

Description: Response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1

Measure: Objective confirmed response

Time: Up to 2 years

Description: Response will be assessed using the RECIST criteria 1.1.

Measure: Duration of response

Time: Up to 2 years

Description: Response will be assessed using the RECIST criteria 1.1.

Measure: Best response

Time: Up to 2 years

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 V617F

JAK2 V617F) observed in cytogenetic testing and DNA sequencing - Has a prior history of T-acute lymphoblastic lymphoma (T-LBL)/T-acute lymphoblastic leukemia (ALL) Inclusion Criteria: - Patients must have histologically and/or cytologically confirmed solid tumors or B cell lymphoma that are metastatic or unresectable and for which standard treatment options do not exist; patients with hepatocellular carcinoma are eligible without pathological diagnosis if diagnosed on the basis of blood work and imaging - Patients with evaluable disease will be eligible - All patients must have completed any prior chemotherapy, targeted therapy and major surgery, >= 28 days before study entry; for daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of 14 days may be acceptable, and questions related to this can be discussed with study principal investigator - Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%) - Life expectancy of greater than 3 months - Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels - All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade =< 1 (except alopecia) at the time of enrollment - Leukocytes >= 3,000/mcL - Absolute neutrophil count >= 1,500/mcL - Platelets >= 100,000/mcL - Hemoglobin >= 90 g/L (9.0 g/dL) - Creatinine within normal institutional limits OR calculated creatinine clearance >= 60 mL/min/1.73 --- V617F ---

JAK2 V617F) observed in cytogenetic testing and DNA sequencing - Has a prior history of T-acute lymphoblastic lymphoma (T-LBL)/T-acute lymphoblastic leukemia (ALL) Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma Liver Dysfunction Metastatic Malignant Solid Neoplasm Stage III Hepatocellular Carcinoma AJCC v7 Stage IIIA Hepatocellular Carcinoma AJCC v7 Stage IIIB Hepatocellular Carcinoma AJCC v7 Stage IIIC Hepatocellular Carcinoma AJCC v7 Stage IV Hepatocellular Carcinoma AJCC v7 Stage IVA Hepatocellular Carcinoma AJCC v7 Stage IVB Hepatocellular Carcinoma AJCC v7 Unresectable Solid Neoplasm Lymphoma Carcinoma Neoplasms Lymphoma, Non-Hodgkin Carcinoma, Hepatocellular Lymphoma, B-Cell Liver Diseases PRIMARY OBJECTIVES: I. To determine safety, tolerability and recommended phase 2 dose (RP2D) of tazemetostat in patients with varying degrees of hepatic dysfunction. --- V617F ---



HPO Nodes


HPO:
Abnormality of the liver
Genes 848
MKKS TACO1 GLRX5 ABCA1 SLC29A3 BRIP1 LZTR1 ERCC4 ERCC6 ZMPSTE24 MAN2B1 ACADL ACADM ACADVL ACAT1 DNAJC19 MARS ACOX1 NCF1 TMEM216 ETFA ETFB ETFDH SCYL1 TCIRG1 DHDDS MCM4 IKZF1 RPS20 EWSR1 CD46 EXTL3 RRAS ACVRL1 RREB1 ADA ADAR F5 IL17F MECP2 IFT43 MEFV STN1 AXIN1 MEN1 FANCA FANCC FANCD2 FANCE ADK ARL6 FAH TTC8 MET FANCB FANCF FANCG SAA1 FBN1 FBP1 SFTPA2 CIITA SC5D COG6 ARHGAP31 FDX2 AGA AGL JAG1 RNASEH2C MIF FECH AHCY GPC4 WDR35 FGA MLH1 SCO1 CC2D2A ANTXR1 AKT2 NOP10 ALAS2 FGFR2 IFT80 MAD2L2 FH TRMT5 ALDOA DOCK6 ALDOB SLC30A10 SEC23B SDHA FOXF1 SDHB SDHC SDHD DUOXA2 MPI MPL MPV17 FLI1 COG2 KLF11 DCDC2 CLCA4 ANK1 OFD1 OSTM1 SLC25A4 RNASEH2A SFTPC CTC1 ACAD9 SGSH FOS PEX3 CEP290 AGPAT2 DOLK IYD LARS KCNAB2 BBIP1 APC AIRE XIAP SLC39A4 APOA1 NPC2 APOB MSH2 CHD7 FASTKD2 APOC2 TMEM107 APOE CCDC115 TARS2 FANCM SKI AP3B1 FAS NHP2 SKIV2L FASLG SLCO1B1 COA8 SLC2A1 CEP164 PEX26 COG8 RBCK1 SLC4A1 CASK FAN1 WDR19 SLC5A5 MST1 TRMU NBAS HSD3B7 LIPT1 MLH3 VIPAS39 NPHP3 TNFSF11 ARSA ARSB ATP6 GPIHBP1 UBE2T G6PC3 ARVCF KLF1 DYNC2LI1 TRIM32 ASAH1 SLC20A2 SLC25A1 RFXANK SLCO2A1 ASL CIDEC ND1 ND2 SLC22A5 ND3 ND4 ND5 ASS1 ND6 PTRH2 B9D1 ABCB11 DDRGK1 MPC1 TRNE C11ORF95 SMPD1 IFT122 FUCA1 TRNK TRNL1 ATM NGLY1 HAMP RERE TRNN TRNS1 OCLN TRNV TRNW STX11 PRDM16 BBS12 G6PC G6PD SLC37A4 PALLD TRIM37 SLX4 MMUT GAA H19 ALDH7A1 MVK INVS SON SOS1 SOS2 MYC GABRD TRAF3IP2 MYD88 SOX10 UBR1 ATP6V1B2 DNAJB11 INTU MYH9 ANKS6 GALE EOGT GALK1 ATP6AP1 ATP7A DIS3L2 ATP7B GALNS GALT SPIB ATRX SPINK1 AUH TNFSF12 RTEL1 C15ORF41 TMEM165 SPTA1 SDCCAG8 DZIP1L SPTB B2M NAGA NAGLU AKR1D1 CPLX1 GATA2 GATA6 FADD GBA BBS1 BBS2 GBE1 BBS4 SRP54 FGFRL1 UNC13D GCDH NCF2 NCF4 GCGR GCK TNFRSF11A PEX11B GNMT GDF2 ADA2 BCS1L BBS9 DPM1 DPM2 NAGS HESX1 NDUFS4 STAT1 NOD2 BLK BLVRA IFIH1 CDAN1 STK11 NEK1 BMPR1A STX1A NEU1 NEUROD1 GANAB PNPLA6 BPGM STXBP2 GPC3 BRCA1 GLB1 BRAF BRCA2 BTD ABCC8 SURF1 NFKB1 SUMF1 BTK NFKB2 VPS13A C1QBP C1S C4B BMPER GNAS SEMA4A COX4I2 KCNQ1OT1 TALDO1 MYRF AP3D1 GNS ABCG5 ABCG8 NOTCH1 TBX1 ALG1 NOTCH2 CA2 GP1BB NPC1 GPD1 NPHP1 GPI IFT27 TCF4 HNF1A HNF1B TCF3 SLC25A20 RPGRIP1L SLC11A2 NRAS CALR GPR35 TMPRSS6 HGSNAT BAZ1B CASP8 CASP10 CASR IL17RC ADAMTS13 LMNB2 SPECC1L CAV1 BBS5 SLC7A7 TERC TERT TF CBS TFAM CLDN1 POLR3A KRIT1 TFR2 TG TGFB1 MMAA HAVCR2 TBX19 TGFBR2 B9D2 MSH6 GTF2I THRA THRB CD19 MS4A1 DCLRE1C CD27 CD28 GUSB GYPC BTNL2 SCARB2 GYS2 GUCY2D CD40LG TNFRSF13C LRRC8A TNFRSF13B CD70 PLPBP CD79A CD79B CD81 PARN HADHA MRPL3 PAX4 HADHB HADH TNFRSF1A TNFRSF1B SEC63 HBA1 HBA2 POLG2 SLC25A19 KAT6B HBB PC MMAB HBG1 PCCA HBG2 PCCB TNPO3 PCK1 PCK2 TP53 CEP19 COX14 XPR1 PIGM TPI1 CDKN1A HEXB PCSK1 CDKN1B CFH CDKN1C CDKN2A HFE TPO CDKN2B TPP2 CDKN2C H19-ICR TMEM67 USP18 TREX1 POU6F2 HK1 CEL TRHR HLA-B PDGFB PDGFRA MICOS13 PDGFRL PDGFRB VPS45 AMACR CTSC HLA-DRB1 SLC26A4 CFTR PEPD BLNK CTRC PEX1 CLEC7A PEX6 DNAJC21 DPM3 PEX10 HMBS PEX12 PEX13 PEX14 TSC1 TSC2 HMGCL TSHB ATP8B1 TSHR HMGCS2 HMOX1 PFKM HNF4A TRIP13 LYST HNRNPA1 HNRNPA2B1 NLRC4 PGM1 TUFM HIRA RNU4ATAC ABCB4 PHKA2 ERCC8 PHKB PHKG2 LONP1 SERPINA1 AP1S1 ICOS PIGA CLCN7 HOXD13 HPD PIK3CA PIK3R1 HPGD SHPK UCP2 RECQL4 UFD1 A2ML1 PKD1 SNX10 PKD2 PEX16 PKLR PKHD1 TJP2 CYP7B1 ALG8 PLAGL1 IL17RA UQCRC2 ABCC2 PLG UROD UROS HSD17B4 PLIN1 ALG6 EIF2AK3 COG4 VCP PMM2 HJV PMS1 VHL TRAPPC11 PMS2 KIF23 COMT CLIP2 DLL4 WHCR NSD2 NELFA INPP5E IARS POLD1 RRM2B POLG GNPTAB LZTFL1 COX6B1 WT1 POMC COX8A COX10 POU1F1 DUOX2 POU2AF1 COX15 CP TWNK CPA1 XK RFX6 SAMHD1 CPOX PPARG XRCC2 CPT1A XRCC4 IDS CPT2 GTF2IRD1 IDUA NSMCE2 CFI CR2 CTSA SP110 SLC40A1 ZAP70 ALG2 UGT1A1 IFNGR1 IGF2 IGF2R MMEL1 SEC24C LACC1 PRF1 NEK8 IGHM TTC37 IL21R SETBP1 IQCB1 RBPJ LPIN2 PRKAR1A NKX2-5 SLC13A5 APPL1 PRKCD CTBP1 CAVIN1 CTLA4 PRKCSH IGLL1 CTNS CTNNB1 GFM1 IL1RN IL2RA CTSK IL2RG IL6 NEUROG3 ADAMTSL2 IL7R PROP1 ATPAF2 CYBA CYBB CYC1 COX20 TET2 LDLRAP1 IL12A IL12RB1 PRSS1 PRSS2 IFT140 NDUFS7 PSAP TRAF3IP1 EARS2 CYP7A1 PET100 INS IFT172 CYP19A1 PIEZO1 INPPL1 CYBC1 MRPL44 CYP27A1 KIAA0586 VPS33A INSR PSMB4 TMEM199 PSMB8 PSMB9 PDX1 CD55 SLCO1B3 IRF5 DAXX NHLRC2 MCCC1 PTEN NPHP4 RNF43 PLEKHM1 DDOST ITK MKS1 HELLPAR FBXL4 FAM111B JAK2 JAK3 PTPN3 TRMT10C PTPN11 CEP120 PTPRC ALMS1 MOGS CLPB VPS33B TINF2 PAX8 CCDC47 KCNH1 DGUOK DHCR7 DHFR KCNJ11 TMEM70 PEX19 ABCD3 PEX2 PEX5 MFN2 KCNN4 DKC1 KCNQ1 DLD PYGL ATP11C RBM8A DMD RFT1 RMND1 TMEM231 DMPK CARS2 HYMAI KIT TNFSF15 DNASE1L3 RAB27A NR1H4 JAM3 PCSK9 FERMT3 FOXP3 RAD51 RAD51C RNASEH2B KRAS DPAGT1 RAF1 RAG1 RPGRIP1 RAG2 KRT6A KRT6B EFL1 KRT8 PNPLA2 B3GLCT ITCH KRT16 SRD5A3 LHX4 KRT17 RHBDF2 RASA2 WDR34 KRT18 USB1 GNE LYRM4 DYNC2H1 COG7 PIGS GLIS3 AGGF1 FARSB WDR60 MRPS16 FANCL RELA LHX3 LBR REST LCAT RFC2 WRAP53 TYMP BOLA3 RFX5 RFXAP LDLR JMJD1C WDPCP PALB2 LETM1 RHAG NLRP3 TSFM RFWD3 YARS2 BBS10 CEP55 ESCO2 RIT1 TTC7A SLC17A5 LHX1 RMRP MRPS7 RASGRP1 MLXIPL LIG4 LRPPRC LIMK1 LIPA LIPE ABHD5 IL36RN NDUFAF1 LMNA TRIM28 BBS7 SBDS FANCI IER3IP1 SLC25A13 ALG9 SLC25A15 SAR1B CEP83 TTC21B STEAP3 LRP5 BSCL2 ELN LTBP3 C8ORF37 DCTN4 TANGO2 SPRTN SH2D1A LYZ ENG EPCAM CSPP1 TBL2 CD96 EPB41 EPB42 SMAD4 TCTN2 ALG13
B-cell lymphoma
Genes 15
FAS ADA FASLG IGH BIRC3 CASP10 NBN MALT1 PRKCD RASGRP1 FOXP1 PIK3R1 CCND1 BCL10 ATM
Carcinoma
Genes 11
PTEN CDKN1B APC MLH1 MSH2 FGFR3 KIT DKC1 RSPO1 STK11 NLRP1
Decreased liver function
Genes 188
NPC1 CYC1 NHLRC1 TACO1 COX20 MPV17 RNU12 UBR1 IL12A TMEM67 USP18 IL12RB1 CACNA1S COG2 SCO2 TCF4 SLC25A20 EPM2A RPGRIP1L ATP7B GALT SPIB ATRX HLA-B OSTM1 USB1 MICOS13 RTEL1 CTC1 GPR35 COG7 MARS PET100 INPP5E IFT172 IARS ACAD9 AMACR FOS HLA-DRB1 POLG PEX3 NDUFAF3 AGPAT2 COX6B1 TMEM199 AKR1D1 LARS SCYL1 FADD GBA PEX1 PEX6 COX8A COX10 FARSB GBE1 PEX10 PORCN PEX12 PEX13 POU2AF1 XIAP PEX14 PTPN22 IRF5 DAXX IKZF1 FASTKD2 CAV1 CCDC115 PPARG ACVRL1 CPT1A PEX11B WRAP53 SLC7A7 CPT2 GDF2 COQ2 NHP2 LARS2 TERC SP110 TERT BCS1L F5 NDUFB8 TFAM COA8 NDUFS2 CEP164 DDOST F13A1 MEFV NDUFS4 F13B RYR1 PEX26 STT3B ADK BLVRA JAK2 MST1 TRMU FAH MRPS7 NBAS HSD3B7 LIPT1 OTC SERPINA1 TRMT10C LIPA GANAB MMEL1 ATP6 ALMS1 MOGS TINF2 SC5D CCDC47 SURF1 TTC37 DGUOK BTNL2 ALG9 JAG1 SLC25A15 MTM1 IL21R ND1 ND2 ND3 ND4 FECH ND5 ND6 VPS13A PEX19 PEX16 ABCD3 PEX2 SCO1 TJP2 PEX5 DKC1 CC2D2A DLD CYP7B1 ALG8 PARN NOP10 CAVIN1 BSCL2 IFT122 HADHA TRNK TRNL1 HADHB HADH UQCRC2 TRNN RMND1 TRNS1 FH OCLN TRNT TRNV TRNW SH2D1A ALDOB GFM1 ENG TALDO1 ALG6 EIF2AK3 SLC30A10 TNFSF15 TNPO3 COG4 PCK1 PCK2 NR1H4 ALG1 SMAD4 COX14 MPI
Elevated hepatic transaminase
Genes 203
CYC1 CFH CDKN2A HFE TMEM67 USP18 TREX1 GLRX5 MYH9 ERCC4 ATP6AP1 ATP7B ACADM ATRX HLA-B MICOS13 TNFSF12 DNAJC19 MARS IFT172 AMACR TMEM165 ACOX1 MRPL44 KIAA0586 PSMB4 TMEM199 AKR1D1 PSMB8 PSMB9 DNAJC21 DPM3 SRP54 PEX13 DHDDS DAXX IKZF1 HMGCL CD46 ATP8B1 GNMT GDF2 HNF4A ADAR ADA2 BCS1L F5 DPM1 DPM2 DDOST PGM1 HELLPAR FBXL4 ABCB4 ADK JAK2 IFIH1 FAH PHKA2 PHKG2 SERPINA1 TRMT10C FBP1 ICOS BRCA1 ALMS1 BRCA2 CLPB VPS33B SC5D COG6 AGL DGUOK JAG1 NFKB1 NFKB2 RNASEH2C VPS13A AHCY PEX19 PEX16 ABCD3 WDR35 C1QBP CC2D2A DLD CYP7B1 PYGL ALAS2 UQCRC2 GNAS DMD HSD17B4 ALDOB ALG6 EIF2AK3 SLC30A10 COG4 NR1H4 SDHD PMM2 FOXP3 HJV GPD1 RNASEH2B KRAS DPAGT1 MPV17 TRAPPC11 COG2 TCF4 HNF1A HNF1B PNPLA2 DCDC2 SLC25A20 KIF23 RPGRIP1L SRD5A3 OFD1 SLC25A4 GNE RNASEH2A GPR35 COG7 INPP5E IARS ACAD9 POLD1 FOS RRM2B POLG AGPAT2 DOLK LARS FARSB TWNK MRPS16 SAMHD1 CAV1 LBR CCDC115 PPARG CPT1A SLC7A7 CPT2 NSMCE2 TYMP CFI CR2 SP110 CBS TFAM PALB2 COG8 RBCK1 YARS2 TFR2 FAN1 MST1 LHX1 TRMU NBAS HSD3B7 LIPT1 VIPAS39 ABHD5 CD19 MS4A1 SBDS ASL IER3IP1 SLC25A13 SLC25A15 GYS2 SAR1B SLC22A5 TNFRSF13C TNFRSF13B STEAP3 PRKCD CD81 CAVIN1 BSCL2 HADHA MRPL3 ATM HADHB NGLY1 HAMP HADH C8ORF37 TANGO2 OCLN POLG2 HBB CSPP1 G6PC SLC37A4 PALLD TP53 MVK SMAD4
Hepatocellular carcinoma
Genes 54
PMS1 HFE KRAS MST1 FAH IL12A TGFBR2 MET IL12RB1 MSH6 RASGRP1 TCF4 BMPR1A SERPINA1 PMS2 MLH3 IGF2 IGF2R MMEL1 ATP7B SPIB PDGFRL PIK3CA GPR35 SLC25A13 JAG1 AHCY APC MLH1 TJP2 ABCB11 CASP8 HMBS POU2AF1 CASP10 PRKCD IRF5 RPS20 MSH2 SEMA4A CTNNB1 SPRTN UROD FAS FASLG EPCAM G6PC TNFSF15 SLC37A4 TNPO3 H19 TP53 AXIN1 FAN1
Lymphoma
Genes 94
BLM MYC CDKN2A KRAS MYD88 RMRP RAG1 RAG2 MALT1 MSH6 RASGRP1 LIG4 TCF4 PMS2 ICOS NRAS WAS WIPF1 CD19 MS4A1 USB1 IGH TINF2 RB1 DCLRE1C TNFSF12 RTEL1 CTC1 CD27 CD28 PIK3R1 PRF1 NTHL1 TP63 POLE HLA-DRB1 NFKB1 NFKB2 RECQL4 RAD54B CHEK2 TNFRSF13C APC MLH1 TNFRSF13B DKC1 BIRC3 XIAP CASP10 NBN PRKCD COL14A1 FOXP1 CD81 PARN NOP10 CCND1 BCL10 BCL2 MSH2 CHD7 CTLA4 ATM BCL6 MAGT1 RUNX1 TNFRSF1B XRCC4 WRAP53 PTEN MDM2 FAS NHP2 ADA FASLG CR2 SH2D1A TERC AAGAB KIT TERT NSUN2 IL2RG LYST RNF43 ZAP70 DNASE1L3 TP53 RAD54L ITK STAT3 IL7R KIF11 PNP
Neoplasm
Genes 762
CDKN1A CDKN1B CDKN1C CDKN2A HFE CDKN2B CDKN2C GDF5 TSR2 CDKN2D H19-ICR TMEM67 RPL26 RPL27 TREX1 ASXL1 ERBB2 SCN11A POU6F2 ERCC2 RPL35A ERCC3 BRIP1 ERCC4 ABL1 ERCC5 CEBPA ERCC6 PDE6D GCM2 CEL PDGFB PDGFRA PDGFRL MNX1 PDGFRB LEMD3 ENPP1 CTSC ESR1 HLA-DRB1 SLC26A4 MAX APC2 RPS7 TMC6 TMEM216 TRPS1 ACTB RPS10 MC1R MC2R BLNK RPS14 RPS15A ACTG2 ETV6 TCIRG1 DNAJC21 EVC HMBS L2HGDH RPS17 MCM4 RPS19 RPS20 TSC1 TSC2 EWSR1 EXT1 EXT2 RPS24 RPS26 RPS27 ACVR1 EYA1 RPS28 RPS29 MAGT1 ACVRL1 MDH2 MDM2 ADA HNF4A ADAR TRIP13 LYST PICALM ALX4 F13A1 TERF2IP PHF21A F13B RYR1 MAP3K1 AXIN1 TBC1D24 AXIN2 BAP1 CHRNG TWIST1 MEN1 TNFRSF4 FANCA FANCC FANCD2 FANCE TYR GFI1B FAH MET TYROBP FANCB FANCF FANCG SERPINA1 ARID1B SAMD9L AP2S1 MGAT2 DLC1 ICOS DMRT3 SFTPA2 PIGA MGMT MBTPS2 CLCNKB HOXD13 PIK3CA PIK3R1 ACAN FDPS HPGD JAG1 RNASEH2C RECQL4 SCN4A HACE1 RAD54B NR0B1 MITF AHCY GPC4 SCN9A SCN10A HRAS MLF1 MLH1 CTHRC1 TJP2 GTF2H5 FGF3 CC2D2A ANTXR1 LMOD1 PLAG1 FGF8 COL14A1 AKT1 NOP10 ASPSCR1 FGFR1 PLCB4 FGFR3 PLCD1 FGFR2 HAX1 MMP1 MAD2L2 UROD FH MN1 ALK HSPA9 SEC23B SEC23A CARD14 SDHA RAD54L SDHB SDHC SDHD FOXI1 COL1A1 FOXC2 COL2A1 FOXE1 MPL VEGFC ALX3 PMS1 FOXO1 VHL COL4A5 FLI1 MRE11 HSPG2 FLNA KLF11 COL7A1 PIGL SEMA3C BIN1 FLT3 PMS2 FLT4 COL11A2 CIB1 CCDC22 WAS COMP FN1 WIPF1 OFD1 KLF6 ADAMTS3 RNASEH2A LIN28B SFTPC CTC1 PUF60 WHCR NSD2 PPM1D NELFA MAP3K8 INPP5E POLD1 POLE WNT5A POLH GNPTAB SH3GL1 POT1 SH3KBP1 FERMT1 POLR1C WRN TUBB KCNAB2 WT1 APC IKBKG SHH PORCN SHOX BIRC3 POU2AF1 XIAP NLRP1 SAMHD1 XPA MSH2 CHD7 XPC MSH3 ZSWIM6 IDH1 MINPP1 IDH2 TMEM107 TXNRD2 XRCC2 XRCC4 SIX1 SIX3 FANCM SKI FAS FCN3 NHP2 FASLG CR2 CTSA TMEM127 CREB1 CREBBP AR ZAP70 ABCC6 CRKL ZIC2 FAN1 MSR1 MST1 PPP2R1B SETD2 C2CD3 MLH3 PIEZO2 IGF2 ARSA IGF2R MTAP MMEL1 STS GNA14 PMVK SLC12A3 COX1 COX2 UBE2T COX3 IGH SLC17A9 DYNC2LI1 PRCC ELMO2 ASCL1 PRF1 TP63 SLCO2A1 IGHM MTM1 ND1 SETBP1 ND4 ND5 ND6 SNAI2 PTCH2 RNR1 MPLKIP PRKAR1A SMARCB1 ABCB11 WNT10A FLCN SMARCD2 APPL1 PRKCD FOXP1 TRNF C11ORF95 CTBP1 SMO NR5A1 TRNH CTLA4 TRNK IGLL1 TRNL1 ATM RERE MAPK1 CTNNB1 TRNP TRNQ TRNS1 TRNS2 TRNW KDSR SUFU MAP2K1 MAP2K2 CEP57 FZD2 PRDM16 IL2RG G6PC SLC37A4 STAG3 PALLD TRIM37 SLX4 PRLR MUTYH H19 MVD IL7 MVK IL7R SOS1 MYC SOX2 GABRD CYLD MYCN TET2 SOX9 MYD88 IL12A IL12RB1 MYF6 TCTN3 ATP6V1B2 INTU MYH8 MYH11 SAMD9 ATP7A DIS3L2 ATP7B PSAP WWOX MYLK HDAC4 ATR SPIB ACD ATRX SPINK1 ING1 TNFSF12 RTEL1 INHBA PSENEN INS GJB4 CYP11B1 CYP11B2 GJB6 ARHGAP26 KIF1B MAFA RNF113A SRC GAS1 GATA1 CPLX1 GATA2 GATA4 PDX1 BARD1 GBA CDH23 SRP54 FGFRL1 IRF1 NBN SRP72 IRF5 DAXX SRY GCGR CCND1 BCL2 SMARCAD1 GCK NDP KEAP1 TNFRSF10B BCL6 RB1CC1 DCC GPR101 PTCH1 PTEN GDF2 SSX1 BCR SSX2 ADA2 NSUN2 NEK9 DDB2 GDNF DPM1 GINS1 RNF43 GFI1 PTH1R STAR BDNF NAGS STAT1 ITK STAT3 KIAA0753 NOD2 BLK BLM NUTM1 JAK2 STK4 IFIH1 GJA1 STK11 MALT1 NEK1 PTPN3 FAM20C BMPR1A BMPR1B GJB2 GJB3 CCM2 PTPN11 ARL6IP6 KARS NEUROD1 NF1 ANTXR2 DHH GPC3 BRCA1 BRAF BRCA2 NF2 TINF2 SDHAF2 WASHC5 KCNH1 CXCR4 SQSTM1 GLI1 GLI2 GLI3 ABCC8 NBEAL2 DHCR7 DHCR24 KCNJ10 NFKB1 BTK KCNJ11 NFKB2 BUB1 CYP26C1 BUB1B VAMP7 TMC8 MFN2 DKC1 KCNQ1 C1S GNA11 KDR TRPV3 BCL10 DLEC1 GNAI3 GNAQ CDC73 BMPER GNAS SEMA4A GNB1 NME1 TMEM231 FOXH1 PHOX2B CPLANE1 MAPRE2 NODAL TAL1 KIT TAL2 KCNQ1OT1 TNFSF15 DNASE1L3 NOTCH1 NOTCH3 KIF11 CDON DNM2 DNMT3A PNP RAD21 TBX2 RAD51 RAD51C RNASEH2B RAD51D KRAS NPM1 RAF1 KRT1 RAG1 RAG2 CACNA1S KRT5 TCF4 KRT6B EFL1 HNF1A FAT4 HNF1B KRT9 TCF3 CYSLTR2 KRT10 KRT14 EVC2 KCNE3 RARA RPGRIP1L KRT16 CARMIL2 NRAS SRD5A3 KRT17 SASH1 RASA1 RHBDF2 SH2B3 USB1 RB1 TCOF1 NRTN DOCK8 DYNC2H1 CALR GPR35 SLC26A2 NTHL1 NTRK1 MYO1H NUMA1 DVL1 ASCC1 DVL3 NSD1 LAMA3 AGGF1 GPR143 CASP8 B3GALT6 LAMB3 CASP10 GJC2 NR4A3 CASR LAMC2 FANCL RELA OCA2 TDGF1 NUP214 OCRL AIP REST RET MLLT10 RUNX1 WRAP53 CBFB ECE1 GPC6 DLL1 TEK CBL TERC ECM1 AAGAB TERT OGG1 TFAP2A DICER1 WDPCP PALB2 EDN1 LETM1 OPCML MSTO1 EDN3 EDNRB TFE3 ZFPM2 RFWD3 KRIT1 KIF7 SIX6 TG RAD50 ESCO2 VANGL2 RMRP TBX18 TGFBR2 POLR1D SLC22A18 TGIF1 MSH6 COL18A1 USP8 RASGRP1 LIG4 SEMA3D GTF2E2 KLLN RNASEL THPO SF3B1 HMGA2 ALX1 LMNA RNF6 CD19 MS4A1 MTMR14 EGFR LMO1 DCLRE1C ABCA5 LZTS1 LMX1B CD27 TRIM28 CD28 VANGL1 CCBE1 SBDS FANCI BRD4 SLC25A13 MRAP ARMC5 LPP SLC49A4 CHEK2 TREM2 TNFRSF13C FIBP LRRC8A ELANE TNFRSF13B LRP5 CD70 SPRED1 CD79A CD79B CD81 SLC45A2 PRKN PARN HABP2 TAF15 PAX3 EIF2AK4 PAX4 RPL35 PAX6 GREM1 PAX7 SPRTN TNFRSF1B BUB3 KAT6B HBB PDCD10 RNF139 SH2D1A ENG CDH1 EPCAM RSPO1 NNT RPL5 TNPO3 CD96 EP300 DISP1 TOP2A TP53 RPL10 RPL11 SMAD4 RPL15 CDK4 RPL18
Non-Hodgkin lymphoma
Genes 22
MYC FAS ADA FASLG IGH KIT BIRC3 CASP10 NBN CD28 MALT1 PRKCD RASGRP1 FOXP1 PIK3R1 NTHL1 POLE CCND1 BCL10 CTLA4 ATM TNFRSF1B